Related Articles
Serum ProGRP and NSE levels predicting small cell lung cancer transformation in a patient with ALK rearrangement‑positive non‑small cell lung cancer: A case report
Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer
Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non‑small cell lung cancer (Review)
ALK inhibitors and advanced non-small cell lung cancer (Review)
A pregnant patient with ALK‑positive non‑small cell lung cancer treated with alectinib: A case report and review of the literature